Roger Bouillon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roger Bouillon has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Annemieke Verstuyf
Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven 1
4 shared publications Siegfried Segaert
Laboratory for Experimental Medicine and Endocrinology (LEGENDO), Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
4 shared publications- Chantal Mathieu
Clinical and Experimental Endocrinology, University Hospitals Leuven-KUL, Leuven, Belgium
3 shared publications Hugo Degreef
Department of Dermatology, Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
3 shared publicationsKatleen Vantieghem
Laboratory for Experimental Medicine and Endocrinology (LEGENDO), Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
3 shared publications- Lieve Verlinden
Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven 1
3 shared publications
Latest Publications
- 1 July 2010
- Published by Elsevier in The Lancet
- Vol. 376 (9736) , 148-149
Genetic and environmental determinants of vitamin D status
- 1 July 2010
- Published by Elsevier in The Lancet
- Vol. 376 (9736) , 148-149
Genetic and environmental determinants of vitamin D status
- 1 March 2007
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 103 (3-5) , 204-205
13th Workshop consensus for vitamin D nutritional guidelines
- 1 March 2007
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 103 (3-5) , 204-205
13th Workshop consensus for vitamin D nutritional guidelines
- 1 October 2005
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 97 (1-2) , 3-5
NIH deltanoids meeting on Vitamin D and cancer
- 1 October 2005
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 97 (1-2) , 3-5
NIH deltanoids meeting on Vitamin D and cancer
- Open Access
- 1 December 2004
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 89 (12) , 6025-6029
Estrogens Are Essential for Male Pubertal Periosteal Bone Expansion
The skeletal response to estrogen therapy was studied in a 17-yr-old boy with congenital aromatase deficiency. As expected, estrogen therapy (1 mg estradiol valeriate/d from age 17 until 20 yr) normalized total and free testosterone and reduced the rate of bone remodeling. Dual-energy x-ray absorptiometry-assessed areal bone mineral density (BMD) of the lumbar spine and femoral neck increased significantly (by 23% and 14%, respectively), but peripheral quantitative computed tomography at the ultradistal radius revealed no gain of either trabecular or cortical volumetric BMD. The increase in areal BMD was thus driven by an increase in bone size. Indeed, longitudinal bone growth (height, +8.5%) and especially cross-sectional area of the radius (+46%) and cortical thickness (+12%), as measured by peripheral quantitative computed tomography, increased markedly during estrogen treatment. These findings demonstrate that androgens alone are insufficient, whereas estrogens are essential for the process of pubertal periosteal bone expansion typically associated with the male bone phenotype.
- 1 December 2004
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 89 (12) , 6025-6029
Open AccessEstrogens Are Essential for Male Pubertal Periosteal Bone Expansion
The skeletal response to estrogen therapy was studied in a 17-yr-old boy with congenital aromatase deficiency. As expected, estrogen therapy (1 mg estradiol valeriate/d from age 17 until 20 yr) normalized total and free testosterone and reduced the rate of bone remodeling. Dual-energy x-ray absorptiometry-assessed areal bone mineral density (BMD) of the lumbar spine and femoral neck increased significantly (by 23% and 14%, respectively), but peripheral quantitative computed tomography at the ultradistal radius revealed no gain of either trabecular or cortical volumetric BMD. The increase in areal BMD was thus driven by an increase in bone size. Indeed, longitudinal bone growth (height, +8.5%) and especially cross-sectional area of the radius (+46%) and cortical thickness (+12%), as measured by peripheral quantitative computed tomography, increased markedly during estrogen treatment. These findings demonstrate that androgens alone are insufficient, whereas estrogens are essential for the process of pubertal periosteal bone expansion typically associated with the male bone phenotype.
- 1 October 2004
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 89 (10) , 4993-4998
Bone Status and Fracture Prevalence in Russian Adults with Childhood-Onset Growth Hormone Deficiency
The consequences of lifelong untreated childhood-onset GH deficiency (COGHD) on adult bone and especially fracture prevalence are largely unknown due to the lack of data on long-term outcome of untreated patients. Therefore, we studied adult Russian patients (n = 66; 28 females and 38 males) with idiopathic GH-untreated COGHD. Patients had isolated GH deficiency (IGHD; n = 18, age 23 +/- 10 yr) or multiple pituitary hormone deficiency (MPHD) with open (OMPHD; n = 27, age 23 +/- 5 yr) or closed growth plates (CMPHD; n = 21, age 55 +/- 12 yr). Bone mineral content (BMC) and bone mineral density (BMD) values were compared with 821 normal Russian controls. Fracture prevalence was ascertained from medical history and compared with similar data from 333 normal controls. Height sd score was -4.6 (range, -1.8 to -8.1). This represents 82% of the height of normal Russian adults. BMC of the lumbar spine, femoral neck, and total body of patients with IGHD was 54, 71, and 59%, respectively, of that of age- and sex-matched controls (all P < 0 0.001). A similarly decreased BMC (42-69% of expected values) was found for all bone regions of patients with both OMPHD and CMPHD. Mean areal BMD measurements (g/cm(2)) varied (Z scores between -1.8 and -3.0), but the calculated true bone density (g/cm(3)) was normal in patients with IGHD or CMPHD and only slightly decreased (Z score, -0.8) in patients with OMPHD. Lifetime low-energy fracture prevalence was normal in patients with IGHD but substantially exceeded the expected prevalence in OMPHD (odds ratio of fracture = 3.0; 0.6 fractures per patient; P < 0.0001) or CMPHD patients (odds ratio for fracture = 7.4; 2.2 fractures per patient; P < 0.0001). In conclusion, IGHD and MPHD of childhood onset very substantially impair adult height and BMC. Although areal BMD is frankly decreased, volumetric bone density is unaffected, but nevertheless, the fracture prevalence in patients with MPHD is markedly increased. These observations demonstrate that not only volumetric density but also bone mass and shape are major determinants of bone strength.
- 1 October 2004
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 89 (10) , 4993-4998
Bone Status and Fracture Prevalence in Russian Adults with Childhood-Onset Growth Hormone Deficiency
The consequences of lifelong untreated childhood-onset GH deficiency (COGHD) on adult bone and especially fracture prevalence are largely unknown due to the lack of data on long-term outcome of untreated patients. Therefore, we studied adult Russian patients (n = 66; 28 females and 38 males) with idiopathic GH-untreated COGHD. Patients had isolated GH deficiency (IGHD; n = 18, age 23 +/- 10 yr) or multiple pituitary hormone deficiency (MPHD) with open (OMPHD; n = 27, age 23 +/- 5 yr) or closed growth plates (CMPHD; n = 21, age 55 +/- 12 yr). Bone mineral content (BMC) and bone mineral density (BMD) values were compared with 821 normal Russian controls. Fracture prevalence was ascertained from medical history and compared with similar data from 333 normal controls. Height sd score was -4.6 (range, -1.8 to -8.1). This represents 82% of the height of normal Russian adults. BMC of the lumbar spine, femoral neck, and total body of patients with IGHD was 54, 71, and 59%, respectively, of that of age- and sex-matched controls (all P < 0 0.001). A similarly decreased BMC (42-69% of expected values) was found for all bone regions of patients with both OMPHD and CMPHD. Mean areal BMD measurements (g/cm(2)) varied (Z scores between -1.8 and -3.0), but the calculated true bone density (g/cm(3)) was normal in patients with IGHD or CMPHD and only slightly decreased (Z score, -0.8) in patients with OMPHD. Lifetime low-energy fracture prevalence was normal in patients with IGHD but substantially exceeded the expected prevalence in OMPHD (odds ratio of fracture = 3.0; 0.6 fractures per patient; P < 0.0001) or CMPHD patients (odds ratio for fracture = 7.4; 2.2 fractures per patient; P < 0.0001). In conclusion, IGHD and MPHD of childhood onset very substantially impair adult height and BMC. Although areal BMD is frankly decreased, volumetric bone density is unaffected, but nevertheless, the fracture prevalence in patients with MPHD is markedly increased. These observations demonstrate that not only volumetric density but also bone mass and shape are major determinants of bone strength.
- 9 September 2004
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 93 (5) , 951-967
Molecular pathways involved in the anti‐apoptotic effect of 1,25‐dihydroxyvitamin D3 in primary human keratinocytes
We previously reported that 1,25‐dihydroxyvitamin D3 [1,25(OH)2D3] protects primary human keratinocytes against ultraviolet (UV)B‐induced apoptosis. Here, we confirmed the anti‐apoptotic effect of 1,25(OH)2D3 in keratinocytes, using cisplatin and doxorubicin as apoptotic triggers. We further showed that 1,25(OH)2D3 activates two survival pathways in keratinocytes: the MEK/extracellular signal regulated kinase (ERK) and the phosphatidylinositol 3‐kinase (PI‐3K)/Akt pathway. Activation of ERK and Akt by 1,25(OH)2D3 was transient, required a minimal dose of 10−9 M and could be blocked by actinomycin D and cycloheximide. Moreover, inhibition of Akt or ERK activity with respectively a PI‐3K inhibitor (LY294002) or MEK inhibitors (PD98059, UO126), partially or totally suppressed the anti‐apoptotic capacity of 1,25(OH)2D3. Finally, 1,25(OH)2D3 changed the expression of different apoptosis regulators belonging to the Bcl‐2 family. Indeed, 1,25(OH)2D3 treatment increased levels of the anti‐apoptotic protein Bcl‐2 and decreased levels of the pro‐apoptotic proteins Bax and Bad in a time‐ and dose‐dependent way. Induction of Bcl‐2 by 1,25(OH)2D3 was further shown to be mediated by ERK and, to a lesser extent, by Akt. In conclusion, 1,25(OH)2D3 clearly protects keratinocytes against apoptosis (1) by activating the MEK/ERK and the PI‐3K/Akt survival pathways and (2) by increasing the Bcl‐2 to Bax and Bad ratio.
- 9 September 2004
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 93 (5) , 951-967
Molecular pathways involved in the anti‐apoptotic effect of 1,25‐dihydroxyvitamin D3 in primary human keratinocytes
We previously reported that 1,25‐dihydroxyvitamin D3 [1,25(OH)2D3] protects primary human keratinocytes against ultraviolet (UV)B‐induced apoptosis. Here, we confirmed the anti‐apoptotic effect of 1,25(OH)2D3 in keratinocytes, using cisplatin and doxorubicin as apoptotic triggers. We further showed that 1,25(OH)2D3 activates two survival pathways in keratinocytes: the MEK/extracellular signal regulated kinase (ERK) and the phosphatidylinositol 3‐kinase (PI‐3K)/Akt pathway. Activation of ERK and Akt by 1,25(OH)2D3 was transient, required a minimal dose of 10−9 M and could be blocked by actinomycin D and cycloheximide. Moreover, inhibition of Akt or ERK activity with respectively a PI‐3K inhibitor (LY294002) or MEK inhibitors (PD98059, UO126), partially or totally suppressed the anti‐apoptotic capacity of 1,25(OH)2D3. Finally, 1,25(OH)2D3 changed the expression of different apoptosis regulators belonging to the Bcl‐2 family. Indeed, 1,25(OH)2D3 treatment increased levels of the anti‐apoptotic protein Bcl‐2 and decreased levels of the pro‐apoptotic proteins Bax and Bad in a time‐ and dose‐dependent way. Induction of Bcl‐2 by 1,25(OH)2D3 was further shown to be mediated by ERK and, to a lesser extent, by Akt. In conclusion, 1,25(OH)2D3 clearly protects keratinocytes against apoptosis (1) by activating the MEK/ERK and the PI‐3K/Akt survival pathways and (2) by increasing the Bcl‐2 to Bax and Bad ratio.
- 20 March 2004
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 295 (12) , 527-534
Two 14-epi analogues of 1,25-dihydroxyvitamin D3 protect human keratinocytes against the effects of UVB
In search of photoprotective agents, we recently demonstrated a protective effect of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] against different events mediated by ultraviolet B (UVB) in human keratinocytes. Pharmacological doses of 1,25(OH)2D3 were required to obtain significant UVB protection; however, these doses cannot be used in vivo due to the calcemic properties of 1,25(OH)2D3. Therefore, we evaluated the photoprotective capacities of two low-calcemic 14-epi analogues of 1,25(OH)2D3, 19-nor-14-epi-23-yne-1,25(OH)2D3 (TX 522) and 19-nor-14,20-bisepi-23-yne-1,25(OH)2D3 (TX 527). Using cultured human keratinocytes, we investigated the influence of TX 522 and TX 527 on two hallmark events in UVB-irradiated keratinocytes: the induction of apoptosis and the production of interleukin-6 (IL-6). Treatment of the keratinocytes with TX 522 or TX 527, 24 h before irradiation, resulted in a significant and dose-dependent reduction of both UVB-induced apoptosis and IL-6 production. Both analogues were equally efficient in their anti-UVB effects and at least 100 times more potent than 1,25(OH)2D3. We further demonstrated that metallothionein (MT) mRNA expression was clearly induced by 1,25(OH)2D3 and both analogues. MT acts as a radical scavenger in oxygen-mediated UVB injury and its induction may therefore be relevant for the anti-UVB effects of 1,25(OH)2D3 and both analogues. Taken together, these findings create new perspectives for the use of active vitamin D analogues as photoprotective agents.
- 20 March 2004
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 295 (12) , 527-534
Two 14-epi analogues of 1,25-dihydroxyvitamin D3 protect human keratinocytes against the effects of UVB
In search of photoprotective agents, we recently demonstrated a protective effect of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] against different events mediated by ultraviolet B (UVB) in human keratinocytes. Pharmacological doses of 1,25(OH)2D3 were required to obtain significant UVB protection; however, these doses cannot be used in vivo due to the calcemic properties of 1,25(OH)2D3. Therefore, we evaluated the photoprotective capacities of two low-calcemic 14-epi analogues of 1,25(OH)2D3, 19-nor-14-epi-23-yne-1,25(OH)2D3 (TX 522) and 19-nor-14,20-bisepi-23-yne-1,25(OH)2D3 (TX 527). Using cultured human keratinocytes, we investigated the influence of TX 522 and TX 527 on two hallmark events in UVB-irradiated keratinocytes: the induction of apoptosis and the production of interleukin-6 (IL-6). Treatment of the keratinocytes with TX 522 or TX 527, 24 h before irradiation, resulted in a significant and dose-dependent reduction of both UVB-induced apoptosis and IL-6 production. Both analogues were equally efficient in their anti-UVB effects and at least 100 times more potent than 1,25(OH)2D3. We further demonstrated that metallothionein (MT) mRNA expression was clearly induced by 1,25(OH)2D3 and both analogues. MT acts as a radical scavenger in oxygen-mediated UVB injury and its induction may therefore be relevant for the anti-UVB effects of 1,25(OH)2D3 and both analogues. Taken together, these findings create new perspectives for the use of active vitamin D analogues as photoprotective agents.
- Open Access
- 1 January 2004
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 19 (1) , 133-146
The Effects of 1α,25-Dihydroxyvitamin D3 on the Expression of DNA Replication Genes
To identify key genes in the antiproliferative action of 1,25(OH)2D3, MC3T3‐E1 mouse osteoblasts were subjected to cDNA microarray analyses. Eleven E2F‐driven DNA replication genes were downregulated by 1,25(OH)2D3. These results were confirmed by quantitative RT‐PCR in different cell types, showing the general nature of this action of 1,25(OH)2D3. Introduction: 1α,25‐Dihydroxyvitamin D3 [1,25(OH)2D3] has a potent antiproliferative action characterized by a blocked transition from the G1‐ to the S‐phase of the cell cycle. This study aims to identify genes whose expression is markedly altered after 1,25(OH)2D3 treatment in parallel with or preceding the observed G1‐arrest. Materials and Methods: The cDNA microarray technique was used, and the expression of approximately 4600 genes in MC3T3‐E1 mouse osteoblasts was studied 6 and 12 h after treatment with 10−8 M 1,25(OH)2D3. Quantitative reverse transcriptase‐polymerase chain reaction (RT‐PCR) analyses were performed on MC3T3‐E1 cells and on wildtype and vitamin D receptor (VDR) knockout primary murine epidermal keratinocytes (VDRwtMEKs, VDR−/−MEKs) and murine mammary tumor cells (GR) to confirm the microarray data. Results and Conclusions: After 12 h of treatment, in parallel with the 1,25(OH)2D3‐induced G1 arrest, a particular set of DNA replication genes including a cell division cycle 6 homolog, a DNA polymerase alpha subunit, proliferating cell nuclear antigen, two DNA polymerase delta subunits, and flap‐structure specific endonuclease 1, was downregulated at least 2‐fold. These genes are known targets of the E2F family of transcription factors, which are probably the central mediators of this action of 1,25(OH)2D3. Indeed, as shown by transfection assays with an E2F reporter construct, 12‐ and 24‐h treatment of MC3T3‐E1 cells with 1,25(OH)2D3 reduced E2F activity by 49% and 73%, respectively. Quantitative RT‐PCR analyses confirmed the downregulation of these DNA replication genes by 1,25(OH)2D3 in MC3T3‐E1, GR, and VDRwtMEKs cells, but not in VDR−/−MEKs cells, showing that this 1,25(OH)2D3‐driven antiproliferative action is of a general nature and depends on a functional VDR.
- 1 January 2004
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 19 (1) , 133-146
Open AccessThe Effects of 1α,25-Dihydroxyvitamin D3 on the Expression of DNA Replication Genes
To identify key genes in the antiproliferative action of 1,25(OH)2D3, MC3T3‐E1 mouse osteoblasts were subjected to cDNA microarray analyses. Eleven E2F‐driven DNA replication genes were downregulated by 1,25(OH)2D3. These results were confirmed by quantitative RT‐PCR in different cell types, showing the general nature of this action of 1,25(OH)2D3. Introduction: 1α,25‐Dihydroxyvitamin D3 [1,25(OH)2D3] has a potent antiproliferative action characterized by a blocked transition from the G1‐ to the S‐phase of the cell cycle. This study aims to identify genes whose expression is markedly altered after 1,25(OH)2D3 treatment in parallel with or preceding the observed G1‐arrest. Materials and Methods: The cDNA microarray technique was used, and the expression of approximately 4600 genes in MC3T3‐E1 mouse osteoblasts was studied 6 and 12 h after treatment with 10−8 M 1,25(OH)2D3. Quantitative reverse transcriptase‐polymerase chain reaction (RT‐PCR) analyses were performed on MC3T3‐E1 cells and on wildtype and vitamin D receptor (VDR) knockout primary murine epidermal keratinocytes (VDRwtMEKs, VDR−/−MEKs) and murine mammary tumor cells (GR) to confirm the microarray data. Results and Conclusions: After 12 h of treatment, in parallel with the 1,25(OH)2D3‐induced G1 arrest, a particular set of DNA replication genes including a cell division cycle 6 homolog, a DNA polymerase alpha subunit, proliferating cell nuclear antigen, two DNA polymerase delta subunits, and flap‐structure specific endonuclease 1, was downregulated at least 2‐fold. These genes are known targets of the E2F family of transcription factors, which are probably the central mediators of this action of 1,25(OH)2D3. Indeed, as shown by transfection assays with an E2F reporter construct, 12‐ and 24‐h treatment of MC3T3‐E1 cells with 1,25(OH)2D3 reduced E2F activity by 49% and 73%, respectively. Quantitative RT‐PCR analyses confirmed the downregulation of these DNA replication genes by 1,25(OH)2D3 in MC3T3‐E1, GR, and VDRwtMEKs cells, but not in VDR−/−MEKs cells, showing that this 1,25(OH)2D3‐driven antiproliferative action is of a general nature and depends on a functional VDR.
- 16 June 2003
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 89 (4) , 663-673
1,25‐dihydroxyvitamin D3 inhibits ultraviolet B‐induced apoptosis, Jun kinase activation, and interleukin‐6 production in primary human keratinocytes
We investigated the capacity of 1,25‐dihydroxyvitamin D3 [1,25(OH)2D3] to protect human keratinocytes against the hazardous effects of ultraviolet B (UVB)‐irradiation, recognized as the most important etiological factor in the development of skin cancer. Cytoprotective effects of 1,25(OH)2D3 on UVB‐irradiated keratinocytes were seen morphologically and quantified using a colorimetric survival assay. Moreover, 1,25(OH)2D3 suppressed UVB‐induced apoptotic cell death. An ELISA, detecting DNA‐fragmentation, demonstrated that pretreatment of keratinocytes with 1,25(OH)2D3 1 μM for 24 h reduced UVB‐stimulated apoptosis by 55–70%. This suppression required pharmacological concentrations 1,25(OH)2D3 and a preincubation period of several hours. In addition, 1,25(OH)2D3 also inhibited mitochondrial cytochrome c release (90%), a hallmark event of UVB‐induced apoptosis. Furthermore, we demonstrated that 1,25(OH)2D3 reduced two important mediators of the UV‐response, namely, c‐Jun‐NH2‐terminal kinase (JNK) activation and interleukin‐6 (IL‐6) production. As shown by Western blotting, pretreatment of keratinocytes with 1,25(OH)2D3 1 μM diminished UVB‐stimulated JNK activation with more than 30%. 1,25(OH)2D3 treatment (1 μM) reduced UVB‐induced IL‐6 mRNA expression and secretion with 75–90%. Taken together, these findings suggest the existence of a photoprotective effect of active vitamin D3 and create new perspectives for the pharmacological use of active vitamin D compounds in the prevention of UVB‐induced skin damage and carcinogenesis. J. Cell. Biochem. 89: 663–673, 2003.
- 16 June 2003
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 89 (4) , 663-673
1,25‐dihydroxyvitamin D3 inhibits ultraviolet B‐induced apoptosis, Jun kinase activation, and interleukin‐6 production in primary human keratinocytes
We investigated the capacity of 1,25‐dihydroxyvitamin D3 [1,25(OH)2D3] to protect human keratinocytes against the hazardous effects of ultraviolet B (UVB)‐irradiation, recognized as the most important etiological factor in the development of skin cancer. Cytoprotective effects of 1,25(OH)2D3 on UVB‐irradiated keratinocytes were seen morphologically and quantified using a colorimetric survival assay. Moreover, 1,25(OH)2D3 suppressed UVB‐induced apoptotic cell death. An ELISA, detecting DNA‐fragmentation, demonstrated that pretreatment of keratinocytes with 1,25(OH)2D3 1 μM for 24 h reduced UVB‐stimulated apoptosis by 55–70%. This suppression required pharmacological concentrations 1,25(OH)2D3 and a preincubation period of several hours. In addition, 1,25(OH)2D3 also inhibited mitochondrial cytochrome c release (90%), a hallmark event of UVB‐induced apoptosis. Furthermore, we demonstrated that 1,25(OH)2D3 reduced two important mediators of the UV‐response, namely, c‐Jun‐NH2‐terminal kinase (JNK) activation and interleukin‐6 (IL‐6) production. As shown by Western blotting, pretreatment of keratinocytes with 1,25(OH)2D3 1 μM diminished UVB‐stimulated JNK activation with more than 30%. 1,25(OH)2D3 treatment (1 μM) reduced UVB‐induced IL‐6 mRNA expression and secretion with 75–90%. Taken together, these findings suggest the existence of a photoprotective effect of active vitamin D3 and create new perspectives for the pharmacological use of active vitamin D compounds in the prevention of UVB‐induced skin damage and carcinogenesis. J. Cell. Biochem. 89: 663–673, 2003.
- 6 January 2003
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 88 (2) , 332-339
Intestinal calcium absorption: Molecular vitamin D mediated mechanisms
Rickets and hyperparathyroidism caused by a defective Vitamin D receptor (VDR) can be prevented in humans and animals by high calcium intake, suggesting that intestinal calcium absorption is critical for 1,25(OH)2 vitamin D [1,25‐(OH)2D3] action on calcium homeostasis. We assessed the rate of serum 45Ca accumulation within 10 min after oral gavage in two strains of VDR‐knock out (KO) mice (Leuven and Tokyo KO) and observed a threefold lower area under the curve in both KO‐strains. Moreover, we evaluated the expression of intestinal candidate genes, belonging to a new class of calcium channels (TRPV), involved in transcellular calcium transport. The calcium transport protein ECaC2 was more abundantly expressed at mRNA level than ECaC1 in duodenum, but both were considerably reduced (ECaC2 > 90%, ECaC1 > 60%) in the two VDR‐KO strains on a normal calcium diet. Calbindin‐D9K expression was only significantly decreased in the Tokyo KO, whereas PMCA1b expression was normal in both VDR‐KOs. In Leuven wild type mice, a high calcium diet inhibited (> 90%), and 1,25(OH)2D3 or low calcium diet induced (sixfold) duodenal ECaC2 expression and, to a lesser degree, ECaC1 and calbindin‐D9K expression. In Leuven KO mice, however, high or low calcium intake decreased calbindin‐D9K and PMCA1b expression, whereas both ECaC mRNA expressions remained consistently low on any diet. These results suggest that the expression of the novel duodenal epithelial calcium channels (in particular ECaC2 or TRPV6) is strongly vitamin D dependent and that calcium influx, probably interacting with calbindin‐D9K, should be considered as a rate‐limiting step in the process of vitamin D dependent active calcium absorption. J. Cell. Biochem. 88: 332–339, 2003.
- 6 January 2003
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 88 (2) , 332-339
Intestinal calcium absorption: Molecular vitamin D mediated mechanisms
Rickets and hyperparathyroidism caused by a defective Vitamin D receptor (VDR) can be prevented in humans and animals by high calcium intake, suggesting that intestinal calcium absorption is critical for 1,25(OH)2 vitamin D [1,25‐(OH)2D3] action on calcium homeostasis. We assessed the rate of serum 45Ca accumulation within 10 min after oral gavage in two strains of VDR‐knock out (KO) mice (Leuven and Tokyo KO) and observed a threefold lower area under the curve in both KO‐strains. Moreover, we evaluated the expression of intestinal candidate genes, belonging to a new class of calcium channels (TRPV), involved in transcellular calcium transport. The calcium transport protein ECaC2 was more abundantly expressed at mRNA level than ECaC1 in duodenum, but both were considerably reduced (ECaC2 > 90%, ECaC1 > 60%) in the two VDR‐KO strains on a normal calcium diet. Calbindin‐D9K expression was only significantly decreased in the Tokyo KO, whereas PMCA1b expression was normal in both VDR‐KOs. In Leuven wild type mice, a high calcium diet inhibited (> 90%), and 1,25(OH)2D3 or low calcium diet induced (sixfold) duodenal ECaC2 expression and, to a lesser degree, ECaC1 and calbindin‐D9K expression. In Leuven KO mice, however, high or low calcium intake decreased calbindin‐D9K and PMCA1b expression, whereas both ECaC mRNA expressions remained consistently low on any diet. These results suggest that the expression of the novel duodenal epithelial calcium channels (in particular ECaC2 or TRPV6) is strongly vitamin D dependent and that calcium influx, probably interacting with calbindin‐D9K, should be considered as a rate‐limiting step in the process of vitamin D dependent active calcium absorption. J. Cell. Biochem. 88: 332–339, 2003.